CATB - Catabasis Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Catabasis Pharmaceuticals, Inc.

Building 1400E
Suite B14202 One Kendall Square
Cambridge, MA 02139
United States
617-349-1971
http://www.catabasis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Ms. Jill C. MilneCo-Founder, CEO, Pres & Director827.08kN/A1968
Dr. Andrew J. NicholsChief Scientific Officer557.71kN/A1961
Dr. Joanne M. DonovanChief Medical Officer & Sr. VP of Clinical Devel.669.52kN/A1957
Mr. Noah ClauserVP of Fin. & ControllerN/AN/AN/A
Ms. Deirdre A. CunnaneChief Legal Officer & TreasurerN/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Corporate Governance

Catabasis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.